RedHill Biopharma (RDHL) Total Current Liabilities (2022 - 2024)
RedHill Biopharma (RDHL) has disclosed Total Current Liabilities for 3 consecutive years, with $22.2 million as the latest value for Q4 2024.
- Quarterly Total Current Liabilities rose 11.21% to $22.2 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $22.2 million through Dec 2024, up 11.21% year-over-year, with the annual reading at $22.2 million for FY2024, 11.21% up from the prior year.
- Total Current Liabilities for Q4 2024 was $22.2 million at RedHill Biopharma, up from $20.0 million in the prior quarter.
- The five-year high for Total Current Liabilities was $197.5 million in Q4 2022, with the low at $20.0 million in Q4 2023.
- Average Total Current Liabilities over 3 years is $79.9 million, with a median of $22.2 million recorded in 2024.
- The sharpest move saw Total Current Liabilities plummeted 89.88% in 2023, then rose 11.21% in 2024.
- Over 3 years, Total Current Liabilities stood at $197.5 million in 2022, then tumbled by 89.88% to $20.0 million in 2023, then rose by 11.21% to $22.2 million in 2024.
- According to Business Quant data, Total Current Liabilities over the past three periods came in at $22.2 million, $20.0 million, and $197.5 million for Q4 2024, Q4 2023, and Q4 2022 respectively.